Edition:
United Kingdom

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

106.41USD
7:52pm GMT
Change (% chg)

$-1.95 (-1.80%)
Prev Close
$108.36
Open
$109.43
Day's High
$109.66
Day's Low
$106.19
Volume
530,136
Avg. Vol
1,096,277
52-wk High
$119.80
52-wk Low
$73.70

Latest Key Developments (Source: Significant Developments)

Elanco Animal Health Sees FY 2018 Adjusted EPS $1.14 To $1.16
11:02am GMT 

Dec 18 (Reuters) - Elanco Animal Health Inc ::ELANCO ANNOUNCES 2019 FINANCIAL GUIDANCE.SEES FY 2018 EARNINGS PER SHARE $0.15 TO $0.17.SEES FY 2019 REVENUE $3.1 BILLION TO $3.16 BILLION.SEES FY 2019 EARNINGS PER SHARE $0.36 TO $0.48.SEES FY 2018 REVENUE $3.05 BILLION TO $3.08 BILLION.2019 REVENUE IS EXPECTED TO BE BETWEEN $3.10 BILLION AND $3.16 BILLION..2019 CORE REVENUE, WHICH EXCLUDES STRATEGIC EXITS IS EXPECTED TO BE $3.04 BILLION TO $3.10 BILLION.REAFFIRMS ITS EXPECTATION FOR 2018 EPS TO BE IN RANGE OF $1.14 TO $1.16..2019 REVENUE FROM STRATEGIC EXITS IS EXPECTED TO BE APPROXIMATELY $0.06 BILLION.FY2018 EARNINGS PER SHARE VIEW $1.21 -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $3.12 BILLION -- REFINITIV IBES DATA.SEES 2019 ADJUSTED EPS OF $1.02 TO $1.12.FY2019 EARNINGS PER SHARE VIEW $1.08 -- REFINITIV IBES DATA.ELANCO - EPS IN 2018 ARE BEING ADJUSTED ON REPORTED BASIS DUE TO RESTRUCTURING ACTIONS AS PART OF CO'S PRODUCTIVITY AGENDA AND CHARGE.ELANCO ANIMAL - UNDERTAKING STEPS TO OPERATE AS A STAND-ALONE ENTITY, INCLUDING CREATING NECESSARY BACK-OFFICE AND GOVERNANCE STRUCTURES.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $1.14 TO $1.16.  Full Article

Lilly To Acquire Pre-Clinical Pain Program From Hydra Biosciences
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Eli Lilly and Co ::LILLY TO ACQUIRE PRE-CLINICAL PAIN PROGRAM FROM HYDRA BIOSCIENCES.ELI LILLY AND CO - FINANCIAL TERMS FOR AGREEMENT WERE NOT DISCLOSED.ELI LILLY AND CO - TRANSACTION WILL BE REFLECTED IN LILLY'S REPORTED RESULTS AND FINANCIAL GUIDANCE ACCORDING TO GAAP.ELI LILLY AND CO - THERE WILL BE NO CHANGE TO LILLY'S 2018 NON-GAAP EARNINGS PER SHARE GUIDANCE AS A RESULT OF TRANSACTION..ELI LILLY AND CO - ANNOUNCED AGREEMENT WITH HYDRA BIOSCIENCES TO ACQUIRE ALL ASSETS RELATED TO HYDRA'S PRE-CLINICAL PROGRAM OF TRPA1 ANTAGONISTS.  Full Article

Eli Lilly And Evidation Health Expand Collaboration To Analyze Data
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Eli Lilly and Co ::LILLY AND EVIDATION HEALTH EXPAND COLLABORATION TO ANALYZE DATA FROM SMARTPHONES AND CONNECTED SENSORS.ELI LILLY AND CO - TERMS OF AGREEMENT ARE UNDISCLOSED..ELI LILLY AND CO - EXPANDED THEIR COLLABORATION WITH A MULTI-YEAR AGREEMENT.ELI LILLY AND CO - LILLY SCIENTISTS AND RESEARCHERS ACROSS THERAPEUTIC PORTFOLIOS WILL HAVE ACCESS TO EVIDATION'S DATA PLATFORM.  Full Article

Elanco Animal Health Board Authorizes Restructuring Program
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Elanco Animal Health Inc ::ELANCO ANIMAL HEALTH SAYS ON DEC 10, BOARD AUTHORIZED RESTRUCTURING PROGRAM TO STREAMLINE ITS INTERNATIONAL OPERATIONS - SEC FILING.ELANCO ANIMAL HEALTH - RESTRUCTURING REFLECTS CHANGE FROM HAVING PHYSICAL LOCATION TO A DISTRIBUTION MODEL IN CERTAIN COUNTRIES.ELANCO ANIMAL HEALTH - UNDER EFFORTS TO SEPARATE FROM ELI LILLY, BOARD AUTHORIZED WRITE-OFF OF CERTAIN ASSETS NOT TO BE UTILIZED ON ONGOING BASIS.ELANCO ANIMAL HEALTH - EXPECTS TO SUBSTANTIALLY COMPLETE THE RESTRUCTURING ACTIONS BY DECEMBER 2019.ELANCO ANIMAL HEALTH - PROPOSED RESTRUCTURING IS EXPECTED TO LEAD TO A CHARGE OF APPROXIMATELY $37 MILLION IN THE FOURTH QUARTER OF FISCAL YEAR 2018.ELANCO ANIMAL HEALTH - PROPOSED RESTRUCTURING CHARGE TO CONSIST OF OF ABOUT $19 MILLION IN SEVERANCE COSTS & ABOUT $18 MILLION IN ASSET WRITE-OFF EXPENSES.ELANCO ANIMAL HEALTH - TOTAL CASH EXPENDITURES ASSOCIATED WITH PROGRAM ARE EXPECTED TO BE ABOUT $20 MILLION.  Full Article

FDA Grants Fast Track Designation To The Baricitinib Development Program For The Treatment Of Systemic Lupus Erythematosus (SLE)
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Incyte Corp ::FDA GRANTS FAST TRACK DESIGNATION TO THE BARICITINIB DEVELOPMENT PROGRAM FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE).ELI LILLY AND CO - LILLY IS CURRENTLY STUDYING TWO DOSES OF BARICITINIB IN PHASE 3 SLE TRIALS..ELI LILLY - INVESTIGATING BARICITINIB AS POTENTIAL TREATMENT FOR MODERATE TO SEVERE ATOPIC DERMATITIS WITH PHASE 3 RESULTS PROJECTED TO BE SHARED H1 2019.  Full Article

Boehringer Ingelheim And Lilly Partner With Duke Clinical Research Institute
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Eli Lilly and Co ::BOEHRINGER INGELHEIM AND LILLY PARTNER WITH DUKE CLINICAL RESEARCH INSTITUTE TO ADVANCE MULTIDISCIPLINARY CARE FOR PEOPLE WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE.ELI LILLY AND CO - DUKE CLINICAL RESEARCH INSTITUTE'S RESEARCH PROGRAM WILL BE FUNDED BY BOEHRINGER INGELHEIM AND CO.ELI LILLY AND CO - RESEARCHERS WILL BEGIN ENROLLING CLINICS AND PATIENTS FOR STUDY IN 2019 WITH GOAL OF SHARING MAIN RESULTS BY 2021.  Full Article

AC Immune And Lilly Announce License And Collaboration Agreement
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - AC Immune SA ::AC IMMUNE AND LILLY ANNOUNCE LICENSE AND COLLABORATION AGREEMENT.AC IMMUNE - MULTI-YEAR DEAL FOCUSES ON MORPHOMER TAU AGGREGATION INHIBITORS, FOR POTENTIAL TREATMENT OF ALZHEIMER'S, OTHER NEURODEGENERATIVE DISEASES.AC IMMUNE - TO RECEIVE AN INITIAL UPFRONT PAYMENT OF CHF 80 MILLION.AC IMMUNE - ELIGIBLE FOR CHF 60 MILLION IN POTENTIAL NEAR-TERM DEVELOPMENT MILESTONES.AC IMMUNE - ELIGIBLE FOR UP TO ABOUT CHF 1.7 BILLION IN OTHER POTENTIAL DEVELOPMENT, REGULATORY, COMMERCIAL MILESTONES.AC IMMUNE - LILLY TO PURCHASE $50 MILLION NOTE, CONVERTIBLE TO EQUITY POSITION IN CO.AC IMMUNE - TO CONDUCT INITIAL PHASE 1 DEVELOPMENT OF MORPHOMER TAU AGGREGATION INHIBITORS; LILLY TO FUND, CONDUCT FURTHER CLINICAL DEVELOPMENT.AC IMMUNE - LILLY TO GET WORLDWIDE COMMERCIALIZATION RIGHTS FOR TAU AGGREGATION INHIBITORS IN ALZHEIMER'S DISEASE.AC IMMUNE - RETAINED CERTAIN DEVELOPMENT RIGHTS IN ORPHAN INDICATIONS, CO-DEVELOPMENT, CO-PROMOTION OPTIONS IN CERTAIN INDICATIONS OUTSIDE AD.AC IMMUNE - DEAL TO BE REFLECTED IN LILLY'S GAAP REPORTED RESULTS, FINANCIAL GUIDANCE.AC IMMUNE - NO CHANGE TO LILLY'S 2018 NON-GAAP EARNINGS PER SHARE GUIDANCE AS RESULT OF DEAL.  Full Article

Elanco Names Todd Young As Chief Financial Officer
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Elanco Animal Health Inc ::ELANCO NAMES TODD S. YOUNG AS NEW CHIEF FINANCIAL OFFICER.ELANCO ANIMAL HEALTH INC - NAMED TODD S. YOUNG AS EXECUTIVE VICE PRESIDENT & CFO.ELANCO ANIMAL HEALTH INC - YOUNG STARTS HIS NEW POSITION AT ELANCO ON NOVEMBER 1.ELANCO ANIMAL HEALTH - LUCAS MONTARCE, ACTING ELANCO CFO, TO RETURN TO ELI LILLY AND COMPANY AS VP & CFO OF LILLY'S INTERNATIONAL BUSINESS UNIT.  Full Article

Lilly, Dicerna Announce RNAi Licensing, Research Collaboration
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Eli Lilly and Co LLY.N::ELI LILLY AND CO SAYS ANNOUNCE RNAI LICENSING AND RESEARCH COLLABORATION WITH DICERNA PHARMACEUTICALS.ELI LILLY - WILL UTILIZE DICERNA’S GALXC RNAI TECHNOLOGY PLATFORM TO PROGRESS NEW DRUG TARGETS TOWARD CLINICAL DEVELOPMENT, COMMERCIALIZATION.ELI LILLY - RESEARCH COLLABORATION FOCUSED ON POTENTIAL NEW MEDICINES IN AREAS OF CARDIO-METABOLIC DISEASE, NEURODEGENERATION AND PAIN.ELI LILLY - UNDER COLLABORATION TERMS, DICERNA TO RECEIVE UPFRONT PAYMENT OF $100 MILLION, AS WELL AS EQUITY INVESTMENT OF $100 MILLION AT A PREMIUM.ELI LILLY - DICERNA IS ELIGIBLE TO RECEIVE UP TO ABOUT $350 MILLION PER TARGET IN DEVELOPMENT AND COMMERCIALIZATION MILESTONES.ELI LILLY - DICERNA ALSO ELIGIBLE TO TIERED ROYALTIES RANGING FROM MID-SINGLE TO LOW-DOUBLE DIGITS ON PRODUCT SALES.ELI LILLY - DICERNA TO WORK EXCLUSIVELY WITH CO IN NEURODEGENERATION, PAIN FIELDS, AND ON SELECT TARGETS IN CARDIO-METABOLIC DISEASES.ELI LILLY - COS ANTICIPATE COLLABORATING ON MORE THAN TEN TARGETS.  Full Article

Eli Lilly And Co Shares Updated Safety Analysis Of Olumiant In Patients With Moderately-To-Severely Active Rheumatoid Arthritis
Sunday, 21 Oct 2018 

Oct 21 (Reuters) - Eli Lilly And Co LLY.O::ELI LILLY AND CO -LILLY SHARES UPDATED SAFETY ANALYSIS OF OLUMIANT® (BARICITINIB) IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS.ELI LILLY AND CO SAYS INTEGRATED SAFETY ANALYSIS REFLECTS LONG-TERM RESULTS FROM 3,492 TREATED PATIENTS FOR 7,860 PATIENT-YEARS OF EXPOSURE.ELI LILLY AND CO -OVERALL, ADVERSE EVENT IRS PER 100 PYE WERE CONSISTENT WITH PRIOR ANALYSES, DID NOT SHOW EVIDENCE OF INCREASE WITH LONGER-TERM TREATMENT..ELI LILLY AND CO SAYS FOLLOW UP INVESTIGATIONS WILL CONTINUE TO ASSESS OLUMIANT'S LONG-TERM SAFETY PROFILE, INCLUDING MALIGNANCIES, VTE AND MACE..ELI LILLY AND CO SAYS FEWER THAN 1.0 PERCENT OF PATIENTS DISCONTINUED TREATMENT WITH OLUMIANT DUE TO ABNORMAL LAB RESULTS.  Full Article

REFILE-Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial

Dec 17 Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial.